Back

New VHD guidelines – What are the implications for transcatheter aortic valve implantation (TAVI) implanters?

28 August 2017 (13:30 - 13:40)
Organised by:
Congress Presentation Part of: How the new European valvular heart disease guidelines could change the treatment of AS patients? Aortic valve disease Open Access ESC Congress 2017

About the speaker

Photo
Professor Helge Moellmann

St. Johannes-Hospital, Dortmund (Germany)

3 More presentations in this session

Presentation thumbnail
What is the evidence supporting the new valvular heart disease (VHD) guidelines regarding severe aortic stenosis (AS) treatment?
Professor H. Moellmann (Dortmund, DE)
Slides Video
Presentation thumbnail
New VHD guidelines – What are the implications for the cardiologist?
Professor H. Moellmann (Dortmund, DE)
Slides Video
Presentation thumbnail
Summary: key learnings and conclusion - How the new European VHD guidelines could change the treatment of AS patients?
Professor H. Moellmann (Dortmund, DE)
Slides Video

Access the full session

Session thumbnail
How the new European valvular heart disease guidelines could change the treatment of AS patients?

The Event

Event poster

ESC Congress 2017

28 August 2017 13:30 CET
You may be interested in
thumbnail
Congress Session
ESC Paul Hugenholtz Lecture in Innovation
25 August 2023
thumbnail
Congress Session
Imaging the patient with pulmonary hypertension/ case studies and lessons from the 2022 ESC/ERS Guidelines
12 May 2023
thumbnail
Congress Presentation
The influence of the valve expansion on the hemodynamic outcome in valve-in-valve transcatheter aortic valve replacement
31 August 2025
thumbnail
Webinar
2025 ESC Guidelines on Valvular heart disease: what’s new in aortic stenosis
10 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources